期刊文献+

腺病毒载体介导密码子优化型HPV 16 L1基因在哺乳动物细胞中的高效表达及病毒样颗粒的装配 被引量:3

Highly Efficient Expression of Codon-modified HPV16 L1 Gene in Mammalian Cell Using Adenovirus Vector and Assembly of VLPs
下载PDF
导出
摘要 为研究重组腺病毒载体作为HPV16预防性疫苗的可行性,构建了含密码子优化型HPV 16 L1基因的重组腺病毒,并对优化基因在哺乳动物细胞中的表达进行研究。首先按照哺乳动物密码子偏好对野生型HPV16 L1基因进行改造并合成优化基因,命名为mod.HPV16L1。将mod.HPV16L1基因克隆到穿梭质粒PDC316上,与骨架质粒共转染293细胞,在细胞内包装重组腺病毒rAd-mod.HPV16L1。用免疫印迹法检测病毒感染的293T细胞中HPV16L1蛋白的表达。通过Optiprep密度梯度超速离心法纯化HPV16 L1病毒样颗粒(VLPs)。用磷钨酸负染,在电子显微镜下观察HPV16 L1蛋白自我装配形成的VLPs。结果显示,重组腺病毒载体可介导mod.HPV16 L1基因在哺乳动物细胞内的高效表达,L1蛋白可自我装配形成VLPs。 To investigate the feasibility of using recombinant adenovirus vector as prophylactic vaccine against HPV infection, a recombinant adenovirus containing codon modified HPV16 L1 gene was constructed, and the expression of the optimized gene in mammalian cells mediated by adenovirus was evaluated, We optimized the codon usage of wild type HPV 16 L1 gene according to the codon bias of mammalian, and synthesized the fulllength optimized L1 gene, named mod. HPV16L1, which was later cloned to shuttle plasmid PDC316,and cotransfected with the backbone plasmid into 293 cell for tAd production. We detected the expression of HPV16 L1 protein in tAd infected 293T cell by Western blot, and purified the HPV16 virus-like particles that self-assembled in 293T cell using Optiprep density gradient ultracentrifugation. The purified HPV16 L1 virus-like particles were seen under the electron microscope. The results showed the recombinant adenovirus, rAdmod. HPV16L1, mediated highly efficient expression of codon-modified HPV16L1 gene in mammalian cell. The L1 protein could self-assemble into VLPs in mammalian cell.
出处 《病毒学报》 CAS CSCD 北大核心 2006年第2期101-106,共6页 Chinese Journal of Virology
基金 国家高技术"863"计划资助项目(2001AA215221) 国家"973"资助项目(2004C9818806)
关键词 腺病毒 人乳头瘤病毒16型 密码子优化 病毒样颗粒 adenovirus human papillomavirus 16 codon modification virus-like particles(VLPs)
  • 相关文献

参考文献16

  • 1Zur Hausen H.Papillomaviruses and cancer:from basic studies to clinical application[J].Nat Rev Cancer ,2002,2:342-350. 被引量:1
  • 2Clifford G M,Smith J S,Plummer M,et al.Human papillomavirus types in invasive cervical cancer worldwide:a meta-analysis[J].Br J Cancer,2003 ,88:63-73. 被引量:1
  • 3Bosch F X,Manos M M,Munoz N,et al.Prevalence of human papillomavirus in cervical cancer:a worldwide perspective[J].J Natl Cancer Inst ,1995 ,87:796-802. 被引量:1
  • 4Harro C D,Pang Y Y,Roden R B,et al.Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine[J].J Natl Cancer Inst ,2001 ,93:284-292. 被引量:1
  • 5Brown D R,Bryan J T,Schroeder J M,et al.Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles:correlation with competitive radioimmunoassay titer[J].J Infect Dis ,2001,184:1183-1186. 被引量:1
  • 6Koutsky L A,Ault K A,Wheeler C M,et al.A controlled trial of a human papillomavirus type 16 vaccine[J].N Engl J Med ,2002 ,347:1645-1651. 被引量:1
  • 7Lehner T,Wang Y,Cranage M,et al.Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques[J].Nat Med ,1996,2:767-775. 被引量:1
  • 8Xiang Z Q,Pasquini S,Ertl H C J.Induction of genital immunity by DNA priming and intranasal booster immunization with a replication-defective adenoviral recombinant[J].J Immunol,1999,162:6716-6723. 被引量:1
  • 9McConnell M J ,Imperiale M J.Biology of adenovirus and its use as a vector for gene therapy[J].Human Gene Therapy ,2004,15 (11):1022-1033. 被引量:1
  • 10Nakamura Y,Gojobori T,Ikemura T.Codon usage tabulated from international DNA sequence databases:status for the year 2000[J].Nucleic Acids Res ,2000,28:292. 被引量:1

同被引文献32

  • 1刘红莉,陈宏伟,李文生,雷霆,王喆之,王一理,司履生.HPV-16L1植物表达载体的构建及HPV-16L1在转基因烟草中表达的鉴定[J].生物工程学报,2004,20(6):827-831. 被引量:6
  • 2庄敏,谷鸿喜,李迪,崔洪波,刘希君,魏兰兰,凌虹.HPV-16-11 L1双价重组杆状病毒的构建及VLP形成[J].中华微生物学和免疫学杂志,2006,26(9):771-776. 被引量:4
  • 3XU Yu-fei,WANG Qing-yong,ZHANG Hong-tao,HAN Ye-hua,SONG Guo-xing,XU Xue-mei.Encapsidating artificial human papillomavirus-16 mE7 protein in human papillomavirus-6b L1/L2 virus like particles[J].Chinese Medical Journal,2007(6):503-508. 被引量:2
  • 4Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inat, 199.5, 87: 796-802. 被引量:1
  • 5Xiang ZQ, Pasquini S, Ertl HCJ. Induction of genital immunity by DNA priming and intranasal booster immunization with a replicationdefective adenoviral recombinant. J Immunol, 1999,162: 6716-6723. 被引量:1
  • 6Tobery TW, Smith JF, Kuklin N, et al. Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cellmediated immune responses in immunized rhesus macaques. Vaccine, 2003, 21 : 1539-1547. 被引量:1
  • 7Xu Y, Zhang H, Xu X. Enhancement of vaccine potency by fusing modified LTK63 into human papillomavirus type 16 chimeric virus-like particles[J] .FEMS Immunol Med Microbiol, 2008,52(1):99-109. 被引量:1
  • 8Varsani A, Williamson AL, Jaffer MA,et al. A deletion and point mutation study of the human papillomavims type 16 major capsid gene[J]. Virus Res,2006,122(1-2) : 154-163. 被引量:1
  • 9Kondo K, Ochi H, Matsumoto T, et al.Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2- epitopes[J] .J Med Virol, 2008,80(5):841-846. 被引量:1
  • 10Chen XS, Casini G, Harrison SC, et al. Apillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1 [J] .J Mol Biol,2001,307( 1 ) : 173-182. 被引量:1

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部